Urinary pseudouridine in patients with lymphoma: Comparison with other clinical parameters

Clinica Chimica Acta

Volumn 371, Issue 1-2, 2006, Pages 148-151

  Masaki, Yasufumi ^a   Itoh, Kunihiko ^b   Sawaki, Toshioki ^a   Karasawa, Hiromi ^a   Kawanami, Takafumi ^a   Fukushima, Toshihiro ^a   Kawabata, Hiroshi ^a   Wano, Yuji ^a   Hirose, Yuko ^a   Suzuki, Toshio ^c   Sugai, Susumu ^a   Umehara, Hisanori ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c AKITA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Beta 2 microglobulin; Deoxythymidine kinase; Malignant lymphoma; Soluble IL2 receptor; Urinary pseudouridine

Indexed keywords

BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; PSEUDOURIDINE; RECOMBINANT PROTEIN; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; URINALYSIS; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; PSEUDOURIDINE; RECEPTORS, INTERLEUKIN-2; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 33746725280     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.03.002     Document Type: Article

References (33)

1. Pui C.H., Ip S.H., Kung P., et al. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 70 (1987) 624-628
2. Barak V., Ginzburg M., Kalickman I., and Polliack A. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 7 (1992) 431-438
3. Piccinini L., Zironi S., Cenci A.M., Campioli D., Federico M., and Barbieri F. Soluble interleukin-2 receptor and urinary neopterin concentration in malignant lymphoma. Eur J Clin Chem Clin Biochem 31 (1993) 567-574
4. Hamon M.D., Unal E., Macdonald I., Shamim F., Boesen E., and Prentice H.G. Plasma soluble interleukin 2 receptor levels in patients with malignant lymphoma are correlated with disease activity but not cellular immunosuppression. Leuk Lymphoma 10 (1993) 111-115
5. Kalmanti M., Karamolengou K., Dimitriou H., et al. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as marker of disease activity and prognosis in childhood leukemia and lymphoma. Int J Hematol 57 (1993) 147-152
6. Gronowitz J.S., Hagberg H., Kallander C.F., and Simonsson B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47 (1983) 487-495
7. Bogni A., Cortinois A., Grasselli G., et al. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients. J Biol Regul Homeost Agents 8 (1994) 121-125
8. Poley S., Stieber P., Nussler V., Pahl H., and Fateh-Moghadam A. Serum thymidine kinase in non-Hodgkin lymphoma with special regard to multiple myeloma. Anticancer Res 17 (1997) 3025-3029
9. Nakao Y., Matsumoto H., Miyazaki T., et al. Genetic and clinical studies of serum beta 2-microglobulin levels in haematological malignancies. Clin Exp Immunol 46 (1981) 134-141
10. Hagberg H., Killander A., and Simonsson B. Serum beta 2-microglobulin in malignant lymphoma. Cancer 51 (1983) 2220-2225
11. Anderson H., Scarffe J.H., Swindell R., and Crowther D. Serum beta 2-microglobulin in patients with non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 19 (1983) 327-331
12. Constantinides I.P., Pathouli C., Karvountzis G., et al. Serum bata 2 microglobulin in malignant lymphoproliferative disorders. Cancer 55 (1985) 2384-2389
13. Litam P., Swan F., Cabanillas F., et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med 114 (1991) 855-860
14. Dimopoulos M.A., Cabanillas F., Lee J.J., et al. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol 11 (1993) 1108-1111
15. Swan Jr. F., Velasquez W.S., Tucker S., et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 7 (1989) 1518-1527
16. Ferraris A.M., Giuntini P., and Gaetani G.F. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood 54 (1979) 928-932
17. Endrizzi L., Fiorentino M.V., Salvagno L., Segati R., Pappagallo G.L., and Fosser V. Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 18 (1982) 945-949
18. Hagberg H., and Siegbahn A. Prognostic value of serum lactic dehydrogenase in non-Hodgkin's lymphoma. Scand J Haematol 31 (1983) 49-56
19. Suarez C.R., Andreeff M., and Miller D.R. Serum LDH values in childhood acute leukemia and non-Hodgkin's lymphoma. Med Pediatr Oncol 12 (1984) 89-92
20. Fasola G., Fanin R., Gherlinzoni F., et al. Serum LDH concentration in non-Hodgkin's lymphomas. Relationship to histologic type, tumor mass, and presentation features. Acta Haematol 72 (1984) 231-238
21. The international non-Hodgkin's lymphoma prognostic factor project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
22. Borek E., Sharma O.K., and Waalkes T.P. New applications of urinary nucleoside markers. Rec Res Cancer Res 84 (1983) 301-316
23. Sander G., Topp H., Wieland J., Heller-Schoch G., and Schoch G. Possible use of urinary modified RNA metabolites in the measurement of RNA turnover in the human body. Hum Nutr Clin Nutr 40C (1986) 103-118
24. Rasmuson T., and Bjork G.R. Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas. Cancer Detect Prev 6 (1983) 293-296
25. Rasmuson T., and Bjorl G.R. Pseudouridine: a prognostic marker in non-Hodgkin's lymphomas. Cancer Detect Prev 8 (1985) 287-290
26. Itoh K., Mizugaki M., and Ishida N. Detection of increased amounts of urinary peudouridine in cancer patients by use of a monoclonal antibody. Clin Chim Acta 181 (1989) 305-316
27. Itoh K., Konno T., Sasaki T., Ishiwata S., Ishida N., and Mizugaki M. Relationship of urinary pseudouridine and 1-methyl-adenosine to activity of leukemia and lymphoma. Clin Chim Acta 206 (1992) 181-189
28. Motyl T., et al. Comparison of urinary neopterin and pseudouridine in patients with malignant proliferative diseases. Eur J Clin Chem Biochem 31 (1993) 205-209
29. Rasmuson T., and Bjork G.R. Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma. Acta Oncol 34 (1995) 61-67
30. Itoh K., Suzuki K., Ishiwata S., Tezuka T., Mizugaki M., and Suzuki T. Application of a recombinant Fab fragment from a phage display library for sensitive detection of a target antigen by an inhibition ELISA system. J Immunol Methods 223 (1999) 107-114
31. Sander G., Topp H., Heller-Schöch G., Wieland J., and Schöch G. Ribonucleic acid turnover in man: RNA catabolites in urine as measure for the metabolism of each of three major species of RNA. Clin Sci 71 (1986) 367-374
32. Gehrke C.W., Kuo K.C., Davis G.E., Suits R.D., Waalkes T.P., and Brorek E. Quantitative high-performance liquid chromatography of nucleotides in biological materials. J Chromatogr 150 (1978) 455-476
33. Kuo K.C., Gehrke C.W., McCune R.A., Waalkes T.P., and Borek E. Rapid, quantitative high-performance liquid column chromatography of pseudouridine. J Chromatogr 145 (1978) 383-392